Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech (MBRX) announced positive topline results from its Phase 1B/2 clinical trial of Annamycin for soft tissue sarcoma lung metastases, demonstrating a 59.4% clinical benefit rate among responders and improved overall survival and progression-free survival, particularly in patients with fewer prior chemotherapy treatments. The company highlights Annamycin's favorable safety profile and its potential in a market projected to reach $2.6 billion by 2030, with plans to explore further evaluations given its Fast Track Status and Orphan Drug Designation from the FDA. Despite the positive data, no subjects achieved Complete Response, and the company requires significant additional financing.

Analysis

Moleculin Biotech (MBRX) reported encouraging topline efficacy results from its Phase 1B/2 trial of Annamycin for soft tissue sarcoma (STS) lung metastases, demonstrating a Clinical Benefit Rate (CBR) of 59.4% in 32 evaluable patients, comprising 18 subjects with stable disease and one with a partial response. Notably, patients with fewer prior therapies (≤2) receiving Annamycin at ≤330 mg/m² (the RP2D) showed an improved median Overall Survival (OS) of 19.9 months and Progression-Free Survival (PFS) of 127 days. For the Phase 2 cohort (N=17) at 330 mg/m², median PFS was 105 days and OS was 13.5 months, exceeding typical outcomes for second-line monotherapies (8-12 months), despite a median of six prior therapies. The overall trial population (N=36) had a median PFS of 63 days and OS of 411 days. Annamycin maintained a favorable safety profile with no cardiotoxicity observed, and holds FDA Fast Track Status and Orphan Drug Designation for STS and acute myeloid leukemia (AML). The company targets a significant market, projected to reach $2.6 billion by 2030, with 13,500 new STS cases annually. However, no patients achieved a Complete Response (CR), and the company explicitly stated it requires significant additional financing, with no current commitments, to advance clinical trials. Institutional activity in Q1 2025 was mixed, with 11 funds adding MBRX shares and 8 reducing positions; ARMISTICE CAPITAL significantly increased its stake by 932,414 shares (+293.6%), while Renaissance Technologies and UBS Group AG liquidated their holdings. The overall sentiment surrounding the announcement is strongly positive.

Key Decisions for Investors

• Investors should closely monitor upcoming data from further evaluations of Annamycin, particularly focusing on comparative efficacy against existing STS treatments and progress in the AML program.
• The requirement for significant additional financing presents a material risk; progress on securing funding will be a critical catalyst or impediment for MBRX.
• Given the drug's potential in a sizeable market and its favorable safety profile, alongside regulatory designations, consider the risk-reward profile, noting the mixed institutional sentiment which indicates varying interpretations of the current data and future prospects.
• Pay attention to the upcoming KOL webcast on June 5, 2025, for deeper insights into the trial results and the company's strategic plans for Annamycin.